Home Cart Sign in  
Chemical Structure| 497839-62-0 Chemical Structure| 497839-62-0

Structure of AEE788
CAS No.: 497839-62-0

Chemical Structure| 497839-62-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AEE788 is an inhibitor of both EGFR and VEGFR, the IC50s for EGFR and ErbB2 is 2 nM, 6 nM respectively.

Synonyms: NVP-AEE 788

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AEE788

CAS No. :497839-62-0
Formula : C27H32N6
M.W : 440.58
SMILES Code : C[C@@H](NC1=C2C(NC(C3=CC=C(CN4CCN(CC)CC4)C=C3)=C2)=NC=N1)C5=CC=CC=C5
Synonyms :
NVP-AEE 788
MDL No. :MFCD11100351
InChI Key :OONFNUWBHFSNBT-HXUWFJFHSA-N
Pubchem ID :10297043

Safety of AEE788

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AEE788

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR, IC50:2 nM

  • HER2/ErbB2

    HER2/ErbB2, IC50:6 nM

  • ErbB4

    HER4/ErbB4, IC50:160 nM

  • VEGFR1

    FLT1, IC50:59 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Hep3B cells 10 μM 72 h To evaluate the effect of AEE788 on Hep3B cell viability, results showed that after 72 hours, 10 μM AEE788 reduced cell viability up to 85%. Gastroenterology. 2008 Dec;135(6):1972-83, 1983. e1-11
HepG2 cells 10 μM 72 h To evaluate the effect of AEE788 on HepG2 cell viability, results showed that after 72 hours, 10 μM AEE788 reduced cell viability up to 85%. Gastroenterology. 2008 Dec;135(6):1972-83, 1983. e1-11
Huh-7 cells 10 μM 72 h To evaluate the effect of AEE788 on Huh-7 cell viability, results showed that after 72 hours, 10 μM AEE788 reduced cell viability up to 85%. Gastroenterology. 2008 Dec;135(6):1972-83, 1983. e1-11
L3.6pl human pancreatic cancer cells 20 mM AEE788 inhibited phosphorylation of EGFR and VEGFR, reducing proliferation and inducing apoptosis in tumor cells and tumor-associated endothelial cells. Neoplasia. 2005 Jul;7(7):696-704
mouse mesenteric lymphatic endothelial cells 0.25, 0.5, 1.0, 2.5, 5.0 μM 120 min AEE788 inhibited Akt and ERK1/2 phosphorylation, reducing migration, proliferation, and survival of lymphatic endothelial cells Neoplasia. 2006 Sep;8(9):747-57
67NR cells 1 μM 1 hour To test the effect of AEE788 on ErbB receptor activity, results showed that AEE788 could block ErbB receptor activity. Breast Cancer Res. 2013 Jan 23;15(1):R8.
BT474 A3 0.25 μM 6 days AEE788 in combination with endocrine therapy showed significant synergistic anti-proliferative effects in ER-positive cell lines, markedly reducing IC50 values. Br J Cancer. 2010 Apr 13;102(8):1235-43
MCF-7 A2 2 μM 6 days AEE788 in combination with endocrine therapy showed synergistic anti-proliferative effects in ER-positive cell lines, reducing IC50 values. Br J Cancer. 2010 Apr 13;102(8):1235-43

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NU/NU mice Huh7 xenograft model Oral gavage 25 mg/kg 3 times/week until euthanasia To evaluate the anti-tumoral effect of AEE788 in the Huh7 xenograft model, results showed that AEE788 significantly delayed tumor growth and increased survival. Gastroenterology. 2008 Dec;135(6):1972-83, 1983. e1-11
Nude mice Orthotopic human pancreatic cancer L3.6pl cell model Oral gavage 50 mg/kg Three times per week for 5 weeks AEE788 alone or in combination with gemcitabine significantly inhibited tumor growth, reduced microvascular density, and induced apoptosis in tumor cells and tumor-associated endothelial cells. Neoplasia. 2005 Jul;7(7):696-704
Nude mice Orthotopic HT29 human colon cancer model Oral gavage 50 mg/kg Thrice a week for 36 days AEE788 significantly reduced peritumoral lymphatic vessel density and incidence of lymph node metastasis Neoplasia. 2006 Sep;8(9):747-57
BALB/c mice 4T1 and 67NR mammary tumor models Oral 50 mg/kg Three times per week for 12 days To test the effect of AEE788 alone or in combination with dovitinib on tumor growth and metastasis, results showed that the combination significantly inhibited tumor growth and metastasis. Breast Cancer Res. 2013 Jan 23;15(1):R8.
Athymic nude mice Orthotopic human pancreatic cancer model Oral gavage 50 mg/kg 3 times per week for 4 weeks AEE788 alone or in combination with STI571 and gemcitabine significantly inhibited tumor growth and prolonged survival. AEE788 inhibited phosphorylation of EGFR and VEGFR, reduced tumor cell proliferation and microvascular density, and increased apoptosis in tumor cells and tumor-associated endothelial cells. Cancer Res. 2005 Nov 15;65(22):10371-80
Ncr Foxhead nude mice ZR75.1 A3 xenograft model Oral gavage 6.7 mg/ml Once daily for 24 days To evaluate the inhibitory effect of AEE788 alone or in combination with tamoxifen or letrozole on tumor growth. Results showed that letrozole alone was more effective than tamoxifen, and AEE788 combined with letrozole showed a significantly greater inhibition of tumor growth at early time points. Br J Cancer. 2010 Apr 13;102(8):1235-43

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00116376 Glioblastoma Multiforme Phase 1 Phase 2 Completed - United States, California ... More >> University of California at Los Angeles Los Angeles, California, United States, 90095 University of California, San Francisco San Francisco, California, United States, 94143 United States, North Carolina The Brain Tumor Center at Duke, Duke University Medical Center Box 3624 DUMC, Trent Drive, Durham, North Carolina, United States, 27710 United States, Texas University of Texas, MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00118456 Cancer Phase 1 Completed - United States, Connecticut ... More >> Yale Cancer Center New Haven, Connecticut, United States, 06520 United States, Nevada Nevada Cancer Institute Las Vegas, Nevada, United States, 89125 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77054 Institute of Drug Development/Cancer Therapy and Research Center San Antonio, Texas, United States, 78229 Less <<
NCT00107237 Brain and Central Nervous Syst... More >>em Tumors Less << Phase 1 Phase 2 Completed - United States, California ... More >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 United States, North Carolina Duke Univaersity Medical Center Durham, North Carolina, United States, 27710 United States, Texas MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77030 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.35mL

2.27mL

1.13mL

22.70mL

4.54mL

2.27mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories